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Islet Inflammation—The Focus of the 14th IGIS Symposium
The main theme for the Servier-IGIS Meetings, which have been held annually since 2000,
is β-cell biology and insulin secretion. The 14th IGIS symposium in March 2013 focused on
islet inflammation and its impact on islet function. It has been long known that type 1
diabetes (T1D) is associated with immune attacks on the β-cells and therefore that the
immune system with its inflammatory components is a key player in this disease. In recent
years, however, this knowledge has been widened so that metabolic disorders have now also
been established as associated with both the innate and the adaptive immune system. This
also includes the islet dysfunction in type 2 diabetes (T2D). This came about with the
progressive characterization of the islet of Langerhans as a complex structure in which
endocrine cells are interspersed with resident immune cells, and of β-cells as being able to
express chemokines, cytokines and genes encoding innate immune receptors. Altogether this
ensures close interactions with immune resident cells, and, more broadly, with the external
environment of the islet of Langerhans. During the last decade it has also become apparent
that the immune system plays a more subtle role in local and systemic metabolism, a topic
now called immunometabolism. Immunometabolism is therefore highly relevant for obesity
and T2D.
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Systemic Inflammation and Relation to Metabolism
Inflammatory processes are closely linked with glucotoxicity, lipotoxicity, oxidative stress
and endoplasmic reticulum stress, as well as with physical inactivity and other factors
associated with T2D, which is the basis for the hypothesis that low-grade inflammation is a
potential pathway in the pathogenesis of the disease. An early suggestion in this context was
that plasma levels of C-reactive protein (CRP) would predict the development of T2D in
middle-aged males independently of established risk factors [1]. Another important finding
was the association of elevated circulating levels of the proinflammatory IL-18 with
increased risk of T2D [2]. Other proinflammatory markers are also associated with T2D [3].
However, proinflammatory stimuli also induce anti-inflammatory responses as a negative
feedback mechanism, to prevent collateral tissue damage due to an excessive immune
response.
Anti-inflammatory mechanisms may be potential targets for therapy. During the meeting,
such anti-inflammatory markers associated with T2D were discussed. Adiponectin is an
anti-inflammatory protein that may be involved in the pathophysiology of T2D. It is of
interest that its circulating levels are decreased even before the onset of T2D. Other anti-
inflammatory markers are increased in T2D, suggesting compensatory mechanisms,
although these may be inefficient. Interleukin-1 receptor antagonist (IL-1RA), transforming
growth factor-β1 (TGF-β1) and growth differentiation factor-15 (GDF-15) are examples of
such factors that are reduced in T2D. Also other anti-inflammatory markers have also been
studied in relation to T2D, such as omentin, interleukin-10 (IL-10) and secreted frizzled-
related protein-5 (Sfrp5), although their potential role and function remain to be established.
Another systemic factor that may be of relevance is ApoCIII. This is an abundant
apolipoprotein associated with chylomicrons and other lipoproteins in the circulation. It is
largely produced in the liver, where it locally inhibits the activity of lipoprotein lipase.
Elevated circulating ApoCIII is associated with cardiovascular disease. Elevated ApoCIII is
also implicated in T1D and T2D, which may be due to combined action of the
apolipoprotein and elevated circulating free fatty acids through the activation of cytokines
such as STAT1 and NF-kB signalling. ApoCIII may also have direct negative effects on β-
cell function by disrupting β-cell calcium handling, although it is unclear whether β-cells
can sense ApoCIII produced in the liver.
Adipose Tissue Inflammation—A Concept for Metabolic Diseases
The concept of a link between inflammation in various tissues such as fat and metabolic
diseases is not new, and several previous important observations laid the foundation for
discussions during the meeting. Early evidence of linking diabetes with inflammation was
the finding that high-dose sodium salicylate improves glycemic control in subjects with T2D
[4]. Other earlier landmark discoveries include the demonstration of high expression of the
proinflammatory cytokine TNF-α in adipose tissue in obesity and its contribution to insulin
resistance [5], and the accumulation of proinflammatory macrophages in adipose tissue in
obesity [6].
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Owing to a macrophage transcription signature of adipose tissue, the number of
macrophages can be increased from 5% to as much as 50% of the cells in obesity; this is
also associated with insulin resistance. Of particular importance for tissue inflammation in
obesity is the accumulation of M1 macrophages. They accumulate in response to the local
production of fatty acids and they, in turn, produce proinflammatory cytokines such as TNF-
α and IL-1β that further aggravate the local inflammation. The importance of this process
has been documented in studies showing that selective loss of M1 macrophages reduces
local and systemic markers of inflammation and improves insulin sensitivity in high-fat diet
(HFD) fed mice.
Not only macrophages, but also the density of mast cells and neutrophils as well as adaptive
immune cells (CD3+ T-cells, NKT cells and B-cells) are increased in adipose tissue in
obesity, whereas Treg cells drop in number. As Treg cells reduce immunologic responses,
their reduction in adipose tissue in obesity may explain the increased inflammation. Thus,
metabolic processes, especially related to obesity and insulin resistance, activate both the
innate and adaptive arms of the immune system, although it is still unclear which antigen
may regulate Tregs.
At the meeting, several novel and exciting findings were discussed which shed a new light
on the mechanisms underlying the accumulation of inflammatory cells in adipose tissue in
obesity. Increased lipolysis with formation of fatty acids, which in turn activate toll-like
receptors, among others, is important, as this initiates accumulation of numerous types of
immune cells in fat tissue, mainly M1 macrophages and T-cells. Hence, accumulation of
immune cells in adipose tissue in obesity is intimately coupled to the local regulation of
lipolysis, but has also consequences for metabolism in general. Thus, adipose tissue
inflammatory cells talk with the pancreatic islets, resulting in both impaired β-cell function
and recruitment of macrophages and T cells to the islets. Such local islet inflammation may
be of particular importance in obesity and after intake of a fat-rich diet, may even be a cause
of the β-cell dysfunction in T2D and thus a potential target for therapy. On the other hand,
there is also accumulating evidence that recruitment of M2 macrophages to adipose tissue in
obesity counteracts obesity, increases insulin sensitivity and might serve as a ‘sink’ for fatty
acids to prevent their further release into the circulation. Therefore, inflammation may not
be only associated with detrimental actions on metabolism but also be beneficial, thus being
both a ‘good guy’ and a ‘bad guy’.
Interaction Between Adipose Tissue and Pancreatic Islets
Since the discovery of increased production of the proin-flammatory cytokine TNF-α in
adipose tissue of obese mice, various cytokines and chemokines such as leptin, IL-6 and
MCP-1 were found to be produced by adipose tissue and over-produced during adiposity.
This may have direct implication for islet function, and suggests an immunometabolic cross-
talk between the fat tissue and the β-cells. While leptin and adiponectin are produced
exclusively in adipocytes, TNF-α, IL-6 and MCP-1 are expressed at high levels in
macrophages as well. Excess of nutrients such as glucose and free fatty acids induce local
production of cyotokines and chemokines in adipocytes, and accumulation of macrophages
in adipose tissue. These factors not only trigger an inflammatory response in adipose tissue
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itself, but are also released into the circulation, eventually promoting inflammation in other
tissues including pancreatic islets. IL-6 in particular is an interesting cytokine; whether IL-6
is deleterious or beneficial is currently a matter of debate. Increased circulating IL-6
concentrations have been found to be associated with the development of obesity and T2D,
with adipose tissue being the major source of the cytokine. On the other hand, it has been
reported that production and release of IL-6 from skeletal muscle in response to muscle
contraction during exercise improves systemic insulin sensitivity. Very recently, elevated
levels of circulating IL-6 were shown to increase the plasma concentrations of glucagon-like
peptide 1 (GLP-1), an incretin hormone, improving insulin secretion and glucose
intolerance. Intriguingly, IL-6 increased the production and secretion of GLP-1 not only
from intestinal L-cells, but also from pancreatic α-cells through increased proglucagon and
prohormone convertase 1/3 expression. Thus, IL-6 mediates the interaction between insulin-
sensitive tissues such as adipose tissue and pancreatic islets, enabling adaption to changes in
insulin demand. Leptin is another example. In addition to its role as a satiety factor, leptin is
thought to act as a proinflammatory cytokine. It promotes autoimmune diseases including
autoimmune diabetes in NOD mice, rheumatoid arthritis, inflammatory bowel disease and
multiple sclerosis. In human islets, leptin was shown to induce β-cell apoptosis by
increasing release of IL-1β and decreasing IL-1RA. Thus, it has become apparent that
cytokines released from insulin target tissues such as adipose tissue and mediate
inflammation in the islets.
Islet Inflammation
It is well established that islet inflammation (insulitis) associated with autoimmune
processes, which eventually causes β-cell dysfunction and death, is a characteristic of T1D.
Production of interferon-γ (IFN-γ) by diabetogenic T-cells has been thought to be an
important contributor to the pathogenesis of T1D. In addition, the innate inflammatory
cytokines TNF-α, and IL-1β also impact β-cells during the autoimmune process of the
disease. An increased expression of class I major histocompatibility complex (MHC)
molecules on β-cells, related with increased class I interferon gene expression in some
models, is constantly observed as an early event in β-cell autoimmunity in experimental
models and in humans. Evidence has also been given in the meeting linking the presentation
of autoantigens by class I MHC molecules, their landmark function, to the islet metabolic
environment, for example hyperglycaemia. In contrast to T1D, the concept of islet
inflammation in T2D is relatively recent. Although obesity and T2D are associated with
systemic and chronic inflammation(so-called low-grade inflammation), accumulating
evidence indicates that local inflammation in the islets contributes to the pathogenesis of
T2D. It was first reported that exposure to high glucose causes IL-1β secretion from β-cells,
indicating that a non-autoimmune mechanism can induce proinflammatory cytokine
production in the islet cells [7]. To date, two independent studies have shown increased
macrophages in the islets of human T2D. In addition, morphological studies revealed that
islets of various animal models of T2D, including HFD-fed mice, db/db mice, GK rats and
Zucker rats, showed typical features of inflammation such as increased numbers of islet
macrophages and expression of cytokines and chemokines. GK rats especially, in which
impaired β-cell function rather than insulin resistance is the primary defect in the
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pathogenesis of diabetes, show increased expressions of cytokines such as IL-1β, IL-6, and
TNF-α, and increased chemokines such as CXCL1, MCP-1 and MIP-1α. This suggests that
inflammation likely occurs specifically in the islets of T2D. Macrophages are comprised of
two subsets, M1 (proinflammatory) and M2 (anti-inflammatory). In the normal state, islet-
resident macrophages are largely of the M2 phenotype, whereas in T2D animal models
macrophages with M1 phenotype are relatively increased. This suggests that macrophage
polarity is shifted towards M1 in the islets of T2D.
Nutrients such as glucose and free fatty acids induce various cytokines and chemokines from
human and rodent islets, which promote migration of monocytes and neutrophils. An
attractive model has been proposed [8], according to which free fatty acids and AGE
(advanced glycation end-products) bind their receptors (i.e., toll-like receptor [TLR]2 or
TLR4 and RAGE, respectively), leading to NF-κB activation and the production of various
proinflammatory cytokines and chemokines. In addition, high concentrations of glucose
induce NLRP3 (NOD-, LRR- and pyrin domain-containing 3) inflammasomes in both β-
cells and macrophages. Human islet amyloid polypeptide (IAPP) also appears to contribute
to the induction of IL-β production in the islets through the NLRP3 inflammasome.
Interestingly, relatively high concentrations of IL-1β suppress both β-cell proliferation and
insulin secretion, whereas relatively low concentrations exert beneficial effects including
stimulation of β-cell proliferation and insulin secretion, suggesting that IL-1β plays a dual
role in a concentration-dependent manner.
Autophagy in the β-cells is another emerging field. Autophagy is the major intracellular
degradation system by which cytosolic materials are delivered to and degraded in the
lysosome. Chronic suppression of β-cell autophagy activity causes reduction in both β-cell
mass and insulin secretion, suggesting that basal autophagy is important for maintenance of
β-cell well-being. As autophagy deficiency is a proinflammatory condition, dysregulation of
autophagy in pancreatic islets likely contributes to the development of islet dysfunction by
inducing recruitment of inflammatory cells and promoting inflammatory changes.
Novel Techniques and Approaches
Various new methodologies have recently been developed to study inflammation, and were
discussed during the meeting. For example, non-invasive imaging of the microvasculature
provides a powerful means to monitor inflammation, as alterations in vascular parameters,
such as vasoconstriction, vasodilatation and vascular leakage accompany inflammation. In
fact, changes in vasculature, vascular swelling, and/or endothelial cell modifications precede
insulitis within the islets and in the peri-islet region in streptozotocin-diabetic mice and
NOD mice. High-resolution MRI, which utilizes long-circulating magnetic-fluorescent
nanoparticles, has recently been developed to image microvascular leakage as an indicator
of inflammation, and applied to monitor the initiation and progression of insulitis in NOD
mice in real time. An intriguing method for monitoring inflammatory and immune responses
in pancreatic islets in vivo has been introduced. In this method, pancreatic islets are
transplanted into the anterior chamber of the eye, where they engraft on the iris and become
vascularized and innervated. As the cornea represents a body-window, this method permits
monitoring of the islets at the single-cell level with high-resolution non-invasively and
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longitudinally in diabetic as well as normal states. These new techniques are valuable tools
for the long-term study of islet inflammation and its chronic effects on islet function.
Recently, it has been proposed that the antigen at the onset of metabolic inflammation might
be derived from the environment. In this respect, the intestinal microbiota has drawn
particular attention. The human gastrointestinal tract is inhabited by 1013-14 microorganisms,
more than 10 times the number of cells in the human body. With the advent of the next-
generation sequencing technique, a catalogue of genes that belong to the intestinal
microbiota has been established. To date, more than 4-5 million non-redundant bacterial
genes (metagenome) have been sequenced from the intestinal microbiota of patients. In
addition, the discovery of bacterial DNA within host tissues such as liver, adipose tissue and
blood, permits the establishment of a tissue microbiota. Metagenome analysis by use of
next-generation sequencing should be an important approach to clarification of the
relationship between inflammation and metabolic disorders such as obesity and diabetes.
Inflammation as a Potential Therapeutic Target
Interfering With Macrophage Polarization
The complex process of macrophage recruitment in obesity may be a potential therapeutic
target. Thus, the M1 macrophages in adipose tissue appear of major importance for the local
inflammation. However, macrophages may be polarized to the M2 phenotype, which in
contrast to M1 macrophages, reduce inflammation and improve insulin sensitivity. Directing
polarization may therefore be a potential target for therapy. During the meeting, it was
shown that Trib1, which is an adaptor protein involved in protein degradation of immune-
related transcription factors, controls the differentiation of tissue-resident M2-like
macrophages and is of key importance for maintenance of adipose tissue and suppression of
metabolic disorders. The evidence was based on findings in mice lacking Trib1 in
haematopoietic cells, which show severe lipodystrophy with increased lipolysis in response
to a HFD. These mice develop high triglyceride levels and insulin resistance, together with
increased proinflammatory cytokine production. The mechanisms promoting the M1
phenotype involve PPARγ, IKKβ and JNK. Therefore, inhibition of these signals or directly
promoting M2 phenotype could be an interesting therapeutic approach.
Immunostrategies to Treat Insulitis in T1D
The β-cells are targets in autoimmune T1D and insulin is the major autoantigen recognized
by T-lymphocytes during progression of the disease. During the meeting it was reviewed
that infectious agents, such as enteroviruses, may be triggering this response, although this
concept is still awaiting proof. It was furthermore discussed that several novel genes encode
T-lymphocytic coactivation molecules involved in cross-talk with β-cells and islet resident
immune cells, besides the previously well-described class I and class II MHC molecules.
These genes include ICOS and ICOS ligand (B7RP1). The basis for this assumption was
revealed in studies in which NOD mice devoid of these molecules deviate their
autoimmunity from the islets towards muscles. However, many other genes and molecules
are involved as well, for example insulin, proinsulin and GAD. These are important to
establish as they may form the basis both for diagnostics and immunotherapy of T1D. Many
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strategies have been applied for immunotherapy; unfortunately, although they have been
promising in preventing diabetes in the NOD mouse, they have failed to act in human T1D.
This is explained by the NOD mouse expressing different MHC molecules than humans and,
therefore, that peptides that are potential T-cell targets in humans cannot be tested in mice.
This enforces the need for more proper preclinical models to develop such strategies before
applying to humans, and during the meeting a novel humanized mouse model for T1D was
described. This model (YES) was developed following the generation of mice that are
deficient for endogenous class I and/or class II MHC molecules, instead expressing human
HLA class I and class II alleles. These mice developed insulitis following a single
immunization against a human β-cell line in complete Freund’s adjuvant. With the use of
this model, there may be a hope to develop immune strategies to treat T1D in humans.
Interfering With Islet Inflammation by Rosiglitazone
During the last decade it has also become evident that there is an islet inflammation
component in T2D [9]. Thus, there may exist pathogenic similarities between T1D and T2D.
Indeed, using a T-cell immunoblotting assay, it was shown that islet-reactive T-cells occur
in T2D, and that this is associated with a more severe β-cell dysfunction compared to other
patients with T2D, including antibody-positive patients. This has led to the hypothesis that
environmental factors, mainly related to obesity and high-fat feeding, initiate an islet T-cell
activation which results in β-cell dysfunction as background for T2D. The overall relative
contribution to the T2D β-cell dysfunction of this mechanism vs. mechanisms related to
detrimental islet lipid actions and/or amyloid infiltration was discussed at the meeting. The
proposed islet inflammation with T-cell activity as an important pathogenic factor has also
prompted a study comparing the glucose-lowering actions of rosiglitazone vs. glyburide in
patients with ‘autoimmune’ T2D. It was found that rosiglitazone, which has anti-
inflammatory effects, was associated with improved β-cell function along with a significant
reduction in circulating levels of the proinflammatory cytokines IL-12 and INF-γ and an
increase in adiponectin. Whether the improvement is causally related to suppression of islet
inflammation is a provocative hypothesis that needs further studies.
Targeting NLRP3 Inflammasomes
Caspase-1 is known to be activated by NLRP3 inflammasomes, and as caspase-1 in turn
activates inflammatory cytokines, such as IL-1β, it has been proposed that the NLRP3
inflammasome may be of importance for initiating inflammation in metabolic diseases, as
was reviewed during the meeting. This may also be a novel target for reducing inflammation
and is supported by the beneficial effects of IL-1 antagonism by anakinra in T2D. However,
novel approaches may also involve this target, such as glyceride, which suppresses IAPP-
mediated NLRP3 activation and IL-1β production [10], and interestingly metformin, which
induces same effects. Palmitate and ceramide also activate NLRP3 and may be novel targets.
Target Inflammation With the IL-1β —NF-κB Pathway and TNF-α
IL-1β has been shown to be involved in islet glucose toxicity [7]. During the meeting it was
also discussed that activated caspase-1 cleaves pro-IL-1β into active IL-1β, which in turn
activates NF-κB, resulting in the release of a broad array of cytokines, including IL-1β itself
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(vicious cycle of autoinduction), and chemokines such as IL-8. This has suggested that this
pathway may be a therapeutic target, and previous proof-of-principle studies targeting IL-1β
and its downstream signalling have shown to have beneficial metabolic effects and improve
glycaemia in patients with T2D [11]. A large phase III study of IL-1 antagonism with 17 200
patients using an IL-1β antibody is currently ongoing (ClinicalTrials.gov NCT01327846).
Also TNF-α has been suggested to be a target, owing to its role in insulin resistance [5].
Several studies using TNF-α antagonism have been performed but as reviewed during the
meeting, these have not had optimal design and therefore a state-of-the art clinical study
with a TNF-α antagonist is still warranted in T2D.
Interleukin-6
Blocking IL-6 has been examined as therapy in inflammatory disorders like rheumatoid
arthritis (tocilizumab). Could IL-6 blockade be a potential therapy also of obesity and T2D?
While plausible, this may be problematic considering that IL-6, in addition to being pro-
inflammatory, is also potentially beneficial for metabolic diseases. This duality paradox of
IL-6 was discussed at the meeting. The hypothesis was put forward that IL-6 on one hand
activates the IL-6 receptor, with signalling through gp130 receptors and AMPK activation
which stimulates insulin sensitivity, whereas on the other hand as a circulating factor it may
form a complex with the soluble form of IL-6 receptor, which in a trans-signalling manner
may stimulate the gp130-complex in other cells where insulin resistance is induced. This
hypothesis of dual IL-6 action explains the previous confusions in the field: on one hand
global IL-6 knock out in mice results in obesity and insulin resistance and infusion of IL-6
in humans increases insulin sensitivity, whereas on the other hand IL-6 from the adipose
tissue can induce insulin resistance in the liver. Therefore, blocking IL-6 cannot constitute a
simple treatment for metabolic diseases. Indeed, as expected from this perspective,
tcoilizumab has resulted in increased body weight and hypertriglyceridaemia in several
clinical trials for various inflammatory disorders, mainly rheumatoid arthritis. Studies are
now ongoing to dissect the IL-6 mechanisms of action, in view of improving metabolic
disorders by selective stimulation of the cell-signalling of IL-6, avoiding its trans-signalling.
Lipoxygenases
During the meeting, dysregulation of the path-ways for two oxidoreductases of arachidonic
acid (AA) and other fatty acids (12- and 15-lipoxygenases (LO), 12-LO and 15-LO) was
also discussed. Dysregulation of the 12- and 15-LO pathways were shown to play an active
role in the inflammatory processes associated with diabetes. An important pathway is the
production of 12(S)-hydroxyeicosatetraenoic acids (HETEs), which in obesity are mainly
generated by 12/15-LO. As 12(S)-HETE is associated with increased inflammation both
systemically and within adipose tissue, cross-talk with the 12- and 15-LO pathways may
contribute to the development of diabetes. These pathways are also operative in islets and
may be involved in islet dysfunction during cytokine stress in both T1D and T2D, as 12- and
15-LO pathways increase the production of proinflammatory cytokines in islets. Thus, this
pathway may be a target for treating the islet dysfunction in diabetes, which is supported by
findings of improved glucose homeostasis in mice with genetic deletion of 12- and 15-LO.
Furthermore, targeting genetic deletion in adipose tissue and in islets results both in
improved glycaemia, suggesting that 12-HETE may be involved in the insulin resistance, as
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well as in islet dysfunction in T2D. Generation of specific pharmacologic inhibitors for each
of the LO isoforms in humans would now be of great interest; studies are underway to
identify effective, small molecular inhibitors [12].
Physical Activity
The relation between physical activity and low-grade inflammation was also discussed. It
was thus emphasized that exercise performed at higher intensities with combined aerobic
and resistance exercise training is associated with improvements in the inflammatory profile,
as evident by changes in key mediators of inflammation, most notably increased circulating
levels of IL-6. This has enforced IL-6 as an energy sensor, possibly to preserve fuel
availability during exertion by activating hepatic glucose production and fatty acid
mobilization from fat, possibly mediated by AMPK. IL-6 may also, in association with
exercise, inhibit release of proinflammatory mediators such as TNF-α, and stimulate release
of anti-inflammatory mediators such as IL-8 and MIP-1α. Of importance is that IL-6
induces hepatic glucose release only when muscles are activated, which has supported the
hypothesis that a circulating factor, probably related to IL-6 receptor, needs to be released
together with IL-6 to achieve this effect, reinforcing the trans-signalling mechanism
discussed above. The release of IL-6 is dependent on the intensity and duration of exercise;
these findings provide a novel mechanism underlying the public health benefits of exercise.
Conclusions and Future Challenges
The 14th IGIS meeting provided an exciting update of the current edge knowledge of
inflammatory pathways of relevance for β-cell biology and diabetes pathophysiology and
treatment. It was also obvious that there are still many unknown areas within the context of
islet inflammation. These need to be understood to further delineate the impact of islet
inflammation for the pathophysiology of diabetes, and the potential of targeting
inflammation in its treatment. We need to understand both the potential beneficial impact of
islet inflammation on β-cell function and the mechanisms behind the destructive impact of
inflammation for islet function—we need to understand both the good guy and the bad guy.
Novel techniques would thereby be of importance. This IGIS symposium indeed illuminated
key aspects for future studies which will enhance our understanding of β-cell function under
normal conditions and in diabetes.
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